Your session is about to expire
← Back to Search
ECT204 T-Cell Therapy for Liver Cancer (ARYA-3 Trial)
ARYA-3 Trial Summary
This trial will test a new T-cell therapy to treat advanced liver cancer that has failed other treatments. The goal is to find the safe dose and to see if the treatment works.
ARYA-3 Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowARYA-3 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.ARYA-3 Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My liver cancer affects more than half of my liver.My liver cancer cells test positive for GPC3.I am able to care for myself but may not be able to do active work.I have tried at least two treatments for liver cancer that didn't work or caused side effects.My organs are functioning well.I have a serious health condition like heart failure.My cancer can be measured by scans and has a new part that can be tracked.I am currently undergoing or have recently finished (within 14 days) a treatment specifically targeting liver tumors.My blood flow in the liver or main veins is blocked.My liver cancer cannot be removed by surgery and has come back or spread.I do not have any ongoing serious infections.I have cancer other than liver cancer, but it's not expected to shorten my life within the next 3 years.I am currently receiving treatment for an autoimmune disease.My liver functions well enough for treatment.I have had an organ transplant.
- Group 1: Arm A
- Group 2: Arm B
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there any available slots in this clinical trial for participants?
"According to data hosted on clinicaltrials.gov, this medical research is currently recruiting participants. It was initially released on March 11th 2022 and revised most recently on July 1st 2022."
What goals are being sought after with this medical experiment?
"The primary aim of the trial, to be carried out over 28 days, is determining the Recommended Phase 2 Dose (RP2D) of ECT204 T cells. Secondary objectives include establishing Time of Maximum Concentration (Tmax), evaluating efficacy according to Radiographic Evaluation Criteria for Solid Tumors (RECIST and iRECIST criteria), and ascertaining Maximum Concentration (Cmax)."
To what extent has recruitment for this research endeavor been accomplished?
"Affirmative. According to clinicaltrials.gov, this medical study is actively recruiting participants since its initial posting on March 11th 2022 and most recent update on July 1st 2022. The trial seeks 12 individuals from two different locations for participation."
Share this study with friends
Copy Link
Messenger